L2FU reports 100% recovery of recent study's lost clinical trial patients

NewsGuard 100/100 Score

Recovering unnecessarily lost patient information is now a viable reality.  Lost to follow up (L2FU) rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.

Consequently, regulatory agencies such as the FDA, are requesting that clinical trial sponsors perform comprehensive follow up measures as part of a clinical trial's due diligence efforts or during the conduct of long term safety surveillance studies to monitor patient outcomes.

L2FU, a company specializing in helping clinical trial sites and biopharma companies to locate, contact and collect data from patients deemed 'Lost to Follow-Up', is building a portfolio of successes and an industry reputation for its quality work. The L2FU team proudly reports its latest successful recovery of 100% of a recent study's lost clinical trial patients. This was achieved in only one month to meet a truncated timeline.  The client, a leading integrated managed care organization, with operations in a number of major states across the US and nearly 10 million patient members, required the information rapidly.

The L2FU team worked diligently to recover the lost patients, who were located in other states while acquiring new addresses. "Finding these lost patients several years after their clinical trial participation goes a long way to ensuring that our client's study meets its primary endpoints, and that all of their data is accepted by the Food and Drug Administration (FDA)," noted Bernard Hall, L2FU's manager and main point of contact.

L2FU works closely with clinical research sites and data managers at clinical research organizations (CROs) and biopharmaceutical companies to transmit collected patient data in a secure manner; adhering to HIPAA regulations for privacy and data security. The L2FU team is experienced in proactively recovering lost study subjects and sensitively communicating with patients and their families. Team members are trained on the procedures required for the licensed access to many databases containing millions of vital records.

Employing L2FU to manage lost patients allows already overworked study coordinators to focus their time on active patients in the study, and the L2FU team provides clinical trial sponsors the reassurance that missing patients and required outcome data will be accounted for.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New model predicts kidney injury risk in cancer patients on cisplatin